General
Preferred name
LEFLUNOMIDE
Synonyms
4-Isoxazolecarboxamide, 5-methyl-n-(4-(trifluoromethyl)phenyl)- ()
RS-34821 ()
SU101 ()
HWA486 ()
Leflunomide (HWA486) ()
HWA486, RS-34821, SU101, Arava ()
NSC-759864 ()
Leflunomide winthrop ()
L04AA13 ()
Repso ()
HWA-486 ()
Arava ()
Leflunomide medac ()
Sulol ()
NSC-677411 ()
Leflunomide teva ()
SU-101 ()
Leflunomide ratiopharm ()
Leflunomide-d4 ()
P&D ID
PD000803
CAS
75706-12-6
210165-51-8
1189987-23-2
Tags
prodrug
natural product
drug
available
Approved by
EMA
FDA
First approval
1998
Drug Status
investigational
approved
withdrawn
Drug indication
Arthritis
Coronavirus Disease 2019 (COVID-19)
Multiple sclerosis
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
The active metabolite is eliminated by further metabolism and subsequent renal excretion as well as by direct biliary excretion. In a 28 day study of drug elimination (n=3) using a single dose of radiolabeled compound, approximately 43% of the total radioactivity was eliminated in the urine and 48% was eliminated in the feces. It is not known whether leflunomide is excreted in human milk.; Many drugs are excreted in human milk, and there is a potential for serious adverse reactions in nursing infants from leflunomide.
DESCRIPTION
Inhibits dihydroorotate dehydrogenase.
(GtoPdb)
DESCRIPTION
Immunosuppressive; its metabolite, a malononitrile derivative, inhibits dihydroorotate dehydrogenase (in the de novo pyrimidine synthesis pathway) and several protein tyrosine kinases
(LOPAC library)
DESCRIPTION
Dihydroorotate dehydrogenase inhibitor
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
6
Compound Sets
33
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
LINCS compound set
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
Withdrawn 2.0
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
45
Molecular Weight
270.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
3.25
TPSA
55.13
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.91
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
dihydroorotate dehydrogenase inhibitor
dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor
Target
Dihydroorotate Dehydrogenase
AHR
DHODH
Protein-tyrosine kinase 2
AHR, DHODH, PTK2B
DHODH inhibitor
PTK2B
Bacterial
Endogenous Metabolite
AhR,Dehydrogenase
Pathway
Metabolism
Anti-infection
Metabolic Enzyme/Protease
Indication
rheumatoid arthritis
ATC
L04AA13
Therapeutic Class
Antiinflammatory Agents
Antiviral Agents
Source data
